Allergan To Conduct Additional Tazoral Pivotal Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergan receives a written response from FDA concerning the company's request for dispute resolution over the oral tazarotene NDA, which is "not approvable" at the agency. In addition to the new clinical trial, Allergan will supplement pharmacokinetic and toxicology data.